Trial Profile
A Pilot Study of CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Apr 2022 Planned End Date changed from 31 Dec 2026 to 25 Mar 2027.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 10 Aug 2021 Status changed from recruiting to active, no longer recruiting.